Go Pro

Johnson & Johnson (JNJ) Financials

Johnson & Johnson logo
$263.43 +4.16 (+1.60%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$263.30 -0.13 (-0.05%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Johnson & Johnson

Annual Income Statements for Johnson & Johnson

This table shows Johnson & Johnson's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/3/2016 1/1/2017 12/31/2017 12/30/2018 12/29/2019 1/3/2021 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Net Income / (Loss) Attributable to Common Shareholders
15,409 16,540 1,300 15,297 15,119 14,714 20,878 17,941 35,153 14,066 26,804
Consolidated Net Income / (Loss)
15,409 16,540 1,300 15,297 15,119 14,714 20,878 17,941 35,153 14,066 26,804
Net Income / (Loss) Continuing Operations
15,409 16,540 1,300 15,297 15,119 14,714 17,801 16,370 13,326 14,066 26,804
Total Pre-Tax Income
19,196 19,803 17,673 17,999 17,328 16,497 19,178 19,359 15,062 16,687 32,581
Total Operating Income
17,556 20,371 18,180 19,798 19,814 19,486 19,834 19,955 21,207 20,804 25,287
Total Gross Profit
48,538 50,101 51,011 54,490 54,503 54,157 55,338 55,394 58,606 61,350 63,937
Total Revenue
70,074 71,890 76,450 81,581 82,059 82,584 78,740 79,990 85,159 88,821 94,193
Operating Revenue
70,074 71,890 76,450 81,581 82,059 82,584 78,740 79,990 85,159 88,821 94,193
Total Cost of Revenue
21,536 21,789 25,439 27,091 27,556 28,427 23,402 24,596 26,553 27,471 30,256
Operating Cost of Revenue
21,536 21,789 25,439 27,091 27,556 28,427 23,402 24,596 26,553 27,471 30,256
Total Operating Expenses
30,982 29,730 32,831 34,692 34,689 34,671 35,504 35,439 37,399 40,546 38,650
Selling, General & Admin Expense
21,203 20,067 21,520 22,540 22,178 22,084 20,118 20,246 21,512 22,869 23,676
Research & Development Expense
9,270 9,172 11,002 11,901 12,245 12,340 15,177 14,918 15,398 17,443 14,746
Restructuring Charge
509 491 309 251 266 247 209 275 489 234 228
Total Other Income / (Expense), net
1,640 -568 -507 -1,799 -2,486 -2,989 -656 -596 -6,145 -4,117 7,294
Interest Expense
552 726 934 1,005 318 201 183 276 772 755 971
Interest & Investment Income
128 368 385 611 357 111 53 490 1,261 1,332 1,056
Other Income / (Expense), net
2,064 -210 42 -1,405 -2,525 -2,899 -526 -810 -6,634 -4,694 7,209
Income Tax Expense
3,787 3,263 16,373 2,702 2,209 1,783 1,377 2,989 1,736 2,621 5,777
Net Income / (Loss) Discontinued Operations
- - - - - - 3,077 1,571 21,827 0.00 0.00
Basic Earnings per Share
$5.56 $6.04 $0.48 $5.70 $5.72 $5.59 $7.93 $6.83 $13.88 $5.84 $11.13
Weighted Average Basic Shares Outstanding
2.77B 2.74B 2.69B 2.68B 2.65B 2.63B 2.63B 2.63B 2.53B 2.41B 2.41B
Diluted Earnings per Share
$5.48 $5.93 $0.47 $5.61 $5.63 $5.51 $7.81 $6.73 $13.72 $5.79 $11.03
Weighted Average Diluted Shares Outstanding
2.81B 2.79B 2.75B 2.73B 2.68B 2.67B 2.67B 2.66B 2.56B 2.43B 2.43B
Weighted Average Basic & Diluted Shares Outstanding
2.77B 2.74B 2.71B 2.68B 2.63B 2.63B 2.63B 2.60B 2.41B 2.41B 2.41B
Cash Dividends to Common per Share
$2.95 - $3.32 $3.54 $3.75 $3.98 $4.19 $4.45 $4.70 $4.91 $5.14

Quarterly Income Statements for Johnson & Johnson

This table shows Johnson & Johnson's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 12/28/2025 3/29/2026 6/28/2026
Net Income / (Loss) Attributable to Common Shareholders
4,049 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235 5,534
Consolidated Net Income / (Loss)
4,049 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235 5,534
Net Income / (Loss) Continuing Operations
4,132 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235 5,534
Total Pre-Tax Income
4,826 3,714 5,748 3,338 3,887 13,631 6,491 7,493 4,966 5,990 6,747
Total Operating Income
4,193 5,909 6,276 5,037 3,582 6,182 6,646 7,033 5,426 6,327 7,140
Total Gross Profit
14,597 14,872 15,578 15,508 15,392 14,536 16,115 16,690 16,596 15,956 17,259
Total Revenue
21,395 21,383 22,447 22,471 22,520 21,893 23,743 23,993 24,564 24,062 25,310
Operating Revenue
21,395 21,383 22,447 22,471 22,520 21,893 23,743 23,993 24,564 24,062 25,310
Total Cost of Revenue
6,798 6,511 6,869 6,963 7,128 7,357 7,628 7,303 7,968 8,106 8,051
Operating Cost of Revenue
6,798 6,511 6,869 6,963 7,128 7,357 7,628 7,303 7,968 8,106 8,051
Total Operating Expenses
10,404 8,963 9,302 10,471 11,810 8,354 9,469 9,657 11,170 9,629 10,119
Selling, General & Admin Expense
5,810 5,257 5,681 5,478 6,453 5,112 5,889 5,922 6,753 6,034 6,432
Marketing Expense
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Research & Development Expense
4,538 3,542 3,634 4,952 5,315 3,225 3,516 3,672 4,333 3,563 3,653
Restructuring Charge
56 164 -13 41 42 17 64 63 84 32 34
Total Other Income / (Expense), net
633 -2,195 -528 -1,699 305 7,449 -155 460 -460 -337 -393
Interest Expense
151 155 270 193 137 204 308 245 214 272 281
Interest & Investment Income
363 364 395 292 281 332 260 227 237 229 219
Other Income / (Expense), net
421 -2,404 -653 -1,798 161 7,321 -107 478 -483 -294 -331
Income Tax Expense
694 459 1,062 644 456 2,632 954 2,341 -150 755 1,213
Basic Earnings per Share
$1.61 $1.35 $1.95 $1.12 $1.42 $4.57 $2.30 $2.14 $2.12 $2.17 $2.30
Weighted Average Basic Shares Outstanding
2.53B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B
Diluted Earnings per Share
$1.58 $1.34 $1.93 $1.11 $1.41 $4.54 $2.29 $2.12 $2.08 $2.14 $2.27
Weighted Average Diluted Shares Outstanding
2.56B 2.43B 2.42B 2.43B 2.43B 2.42B 2.42B 2.43B 2.43B 2.45B 2.44B
Weighted Average Basic & Diluted Shares Outstanding
2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B

Annual Cash Flow Statements for Johnson & Johnson

This table details how cash moves in and out of Johnson & Johnson's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/3/2016 1/1/2017 12/31/2017 12/30/2018 12/29/2019 1/3/2021 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Net Change in Cash & Equivalents
-791 5,240 -1,485 524 -802 -3,320 502 -360 7,732 2,246 -4,396
Net Cash From Operating Activities
19,569 18,767 21,056 22,201 23,416 23,536 23,410 21,194 22,791 24,266 24,530
Net Cash From Continuing Operating Activities
19,569 18,767 21,056 22,201 23,416 23,536 23,410 21,194 22,791 24,266 24,530
Net Income / (Loss) Continuing Operations
15,409 16,540 1,300 15,297 15,119 14,714 20,878 17,941 35,153 14,066 26,804
Consolidated Net Income / (Loss)
15,409 16,540 1,300 15,297 15,119 14,714 20,878 17,941 35,153 14,066 26,804
Depreciation Expense
3,746 3,754 5,642 6,929 7,009 7,231 7,390 6,970 7,486 7,339 7,503
Non-Cash Adjustments To Reconcile Net Income
-945 587 467 988 -101 1,190 1,459 1,957 -18,161 3,207 1,403
Changes in Operating Assets and Liabilities, net
1,359 -2,114 13,647 -1,013 1,389 401 -6,317 -5,674 -1,687 -346 -11,180
Net Cash From Investing Activities
-7,735 -4,761 -14,868 -3,167 -6,194 -20,825 -8,683 -12,371 878 -18,599 -23,588
Net Cash From Continuing Investing Activities
-7,735 -4,761 -14,868 -3,167 -6,194 -20,825 -8,683 -12,371 878 -18,599 -23,588
Purchase of Property, Plant & Equipment
-3,463 -3,226 -3,279 -3,670 -3,498 -3,347 -3,652 -4,009 -4,543 -4,424 -4,832
Acquisitions
-954 -4,509 -35,151 -899 -5,810 -7,323 -60 -17,652 -470 -16,929 -17,926
Purchase of Investments
-40,828 -33,950 -6,153 -5,626 -3,920 -21,089 -30,394 -32,384 -10,906 -1,726 -920
Sale of Property, Plant & Equipment
3,464 1,267 1,832 3,203 3,265 305 711 543 358 675 720
Sale and/or Maturity of Investments
34,149 35,780 28,117 4,289 3,387 12,137 25,006 41,609 19,390 2,462 1,661
Other Investing Activities, net
-103 -123 -234 -464 382 -1,508 -294 -478 -2,951 1,343 -2,291
Net Cash From Financing Activities
-11,136 -8,551 -7,673 -18,510 -18,015 -6,120 -14,047 -8,871 -15,825 -3,132 -5,539
Net Cash From Continuing Financing Activities
-11,136 -8,551 -7,673 -18,510 -18,015 -6,120 -14,047 -8,871 -15,825 -3,132 -5,539
Repayment of Debt
-1,169 -4,255 -3,295 -4,207 -2,448 -4,021 -2,878 -8,591 -16,746 -10,954 -14,121
Repurchase of Common Equity
-5,290 -8,979 -6,358 -5,868 -6,746 -3,221 -3,456 -6,035 -5,054 -2,432 -5,953
Payment of Dividends
-8,173 -8,621 -8,943 -9,494 -9,917 -10,481 -11,032 -11,682 -11,770 -11,823 -12,381
Issuance of Debt
2,491 12,115 9,861 85 42 10,822 2,002 16,136 13,743 21,937 23,724
Issuance of Common Equity
- - - - - - 0.00 0.00 4,241 0.00 0.00
Other Financing Activities, net
1,005 1,189 1,062 974 1,054 781 1,317 1,301 -239 140 3,192
Effect of Exchange Rate Changes
-1,489 -215 - - -9.00 89 -178 -312 -112 -289 201
Cash Interest Paid
1,132 1,358 1,826 2,012 1,920 1,745 1,931 1,915 3,602 3,901 3,840
Cash Income Taxes Paid
2,865 2,843 3,312 4,570 4,191 4,619 4,768 5,223 8,574 6,714 6,539

Quarterly Cash Flow Statements for Johnson & Johnson

This table details how cash moves in and out of Johnson & Johnson's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 12/28/2025 3/29/2026 6/28/2026
Net Change in Cash & Equivalents
2,131 3,614 -595 -4,898 4,125 14,369 -19,897 -346 1,478 1,979 -1,266
Net Cash From Operating Activities
7,863 3,657 5,633 7,993 6,983 4,174 3,878 9,169 7,309 2,514 8,616
Net Cash From Continuing Operating Activities
7,863 3,657 5,633 7,993 6,983 4,174 3,878 9,169 7,309 2,514 8,616
Net Income / (Loss) Continuing Operations
4,049 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235 5,534
Consolidated Net Income / (Loss)
4,049 3,255 4,686 2,694 3,431 10,999 5,537 5,152 5,116 5,235 5,534
Depreciation Expense
1,843 1,815 1,782 1,846 1,896 1,772 1,943 1,777 2,011 2,004 1,959
Non-Cash Adjustments To Reconcile Net Income
1,136 487 312 1,534 874 255 494 391 263 342 583
Changes in Operating Assets and Liabilities, net
835 -1,900 -1,147 1,919 782 -8,852 -4,096 1,849 -81 -5,067 540
Net Cash From Investing Activities
-1,202 -464 -13,687 -3,128 -1,320 -297 -18,264 -542 -4,485 -1,040 -1,110
Net Cash From Continuing Investing Activities
-1,202 -464 -13,687 -3,128 -1,320 -297 -18,264 -542 -4,485 -1,040 -1,110
Purchase of Property, Plant & Equipment
-1,589 -807 -976 -1,029 -1,612 -795 -1,043 -1,542 -1,452 -1,049 -1,321
Acquisitions
-470 -1,811 -12,996 -338 -1,784 0.00 -14,458 -1.00 -3,467 0.00 -263
Purchase of Investments
-925 -630 -554 -280 -262 -251 -180 -246 -243 -144 -155
Sale of Property, Plant & Equipment
121 210 363 50 52 279 53 76 312 29 63
Sale and/or Maturity of Investments
3,603 979 727 466 290 218 735 489 219 209 159
Other Investing Activities, net
-1,942 1,595 -251 -1,997 1,996 252 -3,371 682 146 -85 407
Net Cash From Financing Activities
-4,655 546 7,544 -9,882 -1,340 10,422 -5,665 -8,927 -1,369 530 -8,777
Net Cash From Continuing Financing Activities
-4,655 546 7,544 -9,882 -1,340 10,422 -5,665 -8,927 -1,369 530 -8,777
Repayment of Debt
-2,761 -798 -3,883 -4,515 -1,758 -2,831 -2,940 -6,516 -1,834 -5,813 -6,455
Repurchase of Common Equity
-216 -1,475 -136 -539 -282 -2,127 - -1,902 -1,924 -4,028 -221
Payment of Dividends
-2,865 -2,869 -2,985 -2,985 -2,984 -2,989 -3,129 -3,132 -3,131 -3,131 -3,227
Issuance of Debt
1,281 5,265 15,370 -1,991 3,293 17,922 565 1,324 3,913 12,439 707
Other Financing Activities, net
-94 423 -822 148 391 447 -161 1,299 1,607 1,063 419
Effect of Exchange Rate Changes
125 -125 -85 119 -198 70 154 -46 23 -25 5.00

Annual Balance Sheets for Johnson & Johnson

This table presents Johnson & Johnson's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/3/2016 1/1/2017 12/31/2017 12/30/2018 12/29/2019 1/3/2021 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Total Assets
133,411 141,208 157,303 152,954 157,728 174,894 182,018 187,378 167,558 180,104 199,210
Total Current Assets
60,210 65,032 43,088 46,033 45,274 51,237 60,979 55,294 53,495 55,893 55,624
Cash & Equivalents
13,732 18,972 17,824 18,107 17,305 13,985 14,487 12,889 21,859 24,105 19,709
Short-Term Investments
24,644 22,935 472 1,580 1,982 11,200 17,121 9,392 1,068 417 393
Accounts Receivable
10,734 11,699 13,490 14,098 14,481 13,576 15,283 14,039 14,873 14,842 17,178
Inventories, net
8,053 8,144 8,765 8,599 9,020 9,344 10,387 10,268 11,181 12,444 14,191
Prepaid Expenses
3,047 3,282 2,537 2,699 2,392 3,132 3,701 2,876 4,514 4,085 4,153
Plant, Property, & Equipment, net
15,905 15,912 17,005 17,035 17,658 18,766 18,962 17,982 19,898 20,518 23,169
Plant, Property & Equipment, gross
- - - - - - - - - - 54,364
Accumulated Depreciation
- - - - - - - - - - 31,195
Total Noncurrent Assets
57,296 60,264 97,210 89,886 94,796 104,891 102,077 114,102 94,165 103,693 120,417
Goodwill
21,629 22,805 31,906 30,453 33,639 36,393 35,246 36,047 36,558 44,200 48,772
Intangible Assets
25,764 26,876 53,228 47,611 47,643 53,402 46,392 38,489 34,175 37,618 50,403
Noncurrent Deferred & Refundable Income Taxes
5,490 6,148 7,105 7,640 7,819 8,534 10,223 8,947 9,279 10,461 6,874
Other Noncurrent Operating Assets
4,413 4,435 4,971 4,182 5,695 6,562 10,216 9,212 14,153 11,414 14,368
Total Liabilities & Shareholders' Equity
133,411 141,208 157,303 152,954 157,728 174,894 182,018 187,378 167,558 180,104 199,210
Total Liabilities
62,261 70,790 97,143 93,202 98,257 111,616 107,995 110,574 98,784 108,614 117,666
Total Current Liabilities
27,747 26,287 30,537 31,230 35,964 42,493 45,226 55,802 46,282 50,321 54,126
Short-Term Debt
7,004 4,684 3,906 2,796 1,202 2,631 3,766 12,756 3,451 5,983 8,495
Accounts Payable
6,668 6,918 7,310 7,537 8,544 9,505 11,055 9,889 9,632 10,311 11,991
Accrued Expenses
10,851 11,038 14,514 16,981 20,598 25,481 25,707 24,298 26,213 26,129 27,718
Current Deferred & Payable Income Tax Liabilities
750 971 1,854 818 2,266 1,392 1,112 2,220 2,993 3,772 1,388
Current Employee Benefit Liabilities
2,474 2,676 2,953 3,098 3,354 3,484 3,586 3,049 3,993 4,126 4,534
Total Noncurrent Liabilities
34,514 44,503 66,606 61,972 62,293 69,123 62,769 54,772 52,502 58,293 63,540
Long-Term Debt
12,857 22,442 30,675 27,684 26,494 32,635 29,985 26,886 25,881 30,651 39,438
Noncurrent Deferred Revenue
- 0.00 8,472 8,242 7,444 6,559 5,713 4,306 2,881 390 486
Noncurrent Deferred & Payable Income Tax Liabilities
2,562 2,910 8,368 7,506 5,958 7,214 7,487 3,991 3,193 2,448 6,791
Noncurrent Employee Benefit Liabilities
8,854 9,615 10,074 9,951 10,663 10,771 8,898 6,542 7,149 7,255 6,957
Other Noncurrent Operating Liabilities
10,241 9,536 9,017 8,589 11,734 11,944 10,686 10,146 13,398 17,549 9,868
Commitments & Contingencies
- - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
71,150 70,418 60,160 59,752 59,471 63,278 74,023 76,804 68,774 71,490 81,544
Total Preferred & Common Equity
71,150 70,418 60,160 59,752 59,471 63,278 74,023 76,804 68,774 71,490 81,544
Total Common Equity
71,150 70,418 60,160 59,752 59,471 63,278 74,023 76,804 68,774 71,490 81,544
Common Stock
3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120
Retained Earnings
103,879 110,551 101,793 106,216 110,659 113,890 123,060 128,345 153,843 155,791 168,978
Accumulated Other Comprehensive Income / (Loss)
-13,165 -14,901 -13,199 -15,222 -15,891 -15,242 -13,058 -12,967 -12,527 -11,741 -14,930
Other Equity Adjustments
- - - - - - - - - - -75,624

Quarterly Balance Sheets for Johnson & Johnson

This table presents Johnson & Johnson's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 10/1/2023 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 3/29/2026 6/28/2026
Total Assets
166,061 167,558 171,966 181,088 178,287 180,104 193,671 193,389 192,816 200,894 201,061
Total Current Assets
53,703 53,495 57,002 57,817 53,249 55,893 71,551 54,498 54,611 59,173 59,774
Cash & Equivalents
19,728 21,859 25,473 24,878 19,980 24,105 38,474 18,577 18,231 21,688 20,422
Short-Term Investments
3,783 1,068 745 597 317 417 307 303 331 363 336
Accounts Receivable
14,798 14,873 14,946 15,794 16,174 14,842 16,020 17,846 17,611 17,721 19,046
Inventories, net
11,198 11,181 11,383 12,169 12,603 12,444 12,659 13,412 14,146 14,583 15,144
Prepaid Expenses
4,196 4,514 4,455 4,379 4,175 4,085 4,091 4,360 4,292 4,818 4,826
Plant, Property, & Equipment, net
18,821 19,898 19,632 19,748 20,479 20,518 20,871 21,949 22,338 23,270 23,582
Plant, Property & Equipment, gross
45,626 - 47,585 48,035 49,274 - 49,884 52,472 53,375 54,695 55,518
Accumulated Depreciation
26,805 - 27,953 28,287 28,795 - 29,013 30,523 31,037 31,425 31,936
Total Noncurrent Assets
93,537 94,165 95,332 103,523 104,559 103,693 101,249 116,942 115,867 118,451 117,705
Goodwill
36,124 36,558 36,616 44,250 44,799 44,200 44,468 48,117 48,048 48,558 48,479
Intangible Assets
35,021 34,175 34,286 39,725 39,490 37,618 36,755 49,835 48,737 49,061 48,229
Noncurrent Deferred & Refundable Income Taxes
9,259 9,279 10,305 9,004 9,349 10,461 8,492 6,801 6,666 6,727 6,728
Other Noncurrent Operating Assets
13,133 14,153 14,125 10,544 10,921 11,414 11,534 12,189 12,416 14,105 14,269
Total Liabilities & Shareholders' Equity
166,061 167,558 171,966 181,088 178,287 180,104 193,671 193,389 192,816 200,894 201,061
Total Liabilities
94,833 98,784 101,946 109,550 108,129 108,614 115,562 114,916 113,539 119,708 116,090
Total Current Liabilities
44,370 46,282 48,725 53,933 51,759 50,321 56,903 54,180 50,869 57,716 54,895
Short-Term Debt
3,870 3,451 8,550 9,855 4,462 5,983 13,897 11,526 6,387 17,460 11,692
Accounts Payable
8,355 9,632 8,174 8,848 8,954 10,311 9,545 9,464 9,625 10,460 9,223
Accrued Expenses
25,909 26,213 26,505 28,078 29,889 26,129 26,693 28,227 28,957 25,798 29,454
Current Deferred & Payable Income Tax Liabilities
2,899 2,993 3,318 4,309 4,834 3,772 4,217 1,665 1,928 1,087 1,051
Current Employee Benefit Liabilities
3,337 3,993 2,178 2,843 3,620 4,126 2,551 3,298 3,972 2,911 3,475
Total Noncurrent Liabilities
50,463 52,502 53,221 55,617 56,370 58,293 58,659 60,736 62,670 61,992 61,195
Long-Term Debt
26,051 25,881 25,082 31,636 31,289 30,651 38,355 39,235 39,408 37,527 37,344
Noncurrent Deferred Revenue
2,540 2,881 2,881 341 354 390 395 418 418 486 485
Noncurrent Deferred & Payable Income Tax Liabilities
2,623 3,193 3,172 2,635 2,952 2,448 2,428 3,799 5,988 7,011 6,608
Noncurrent Employee Benefit Liabilities
5,687 7,149 7,019 6,919 6,852 7,255 7,046 7,021 6,930 6,760 6,657
Other Noncurrent Operating Liabilities
13,562 13,398 15,067 14,086 14,923 17,549 10,435 10,263 9,926 10,208 10,101
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
71,228 68,774 70,020 71,538 70,158 71,490 78,109 78,473 79,277 81,186 84,971
Total Preferred & Common Equity
71,228 68,774 70,020 71,538 70,158 71,490 78,109 78,473 79,277 81,186 84,971
Total Common Equity
71,228 68,774 70,020 71,538 70,158 71,490 78,109 78,473 79,277 81,186 84,971
Common Stock
3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120
Retained Earnings
152,536 153,843 153,378 155,360 155,179 155,791 162,635 165,371 167,281 169,161 171,665
Accumulated Other Comprehensive Income / (Loss)
-8,780 -12,527 -10,768 -11,253 -12,522 -11,741 -11,740 -14,305 -15,237 -14,831 -13,951
Other Equity Adjustments
-75,648 - -75,710 -75,689 -75,619 - -75,906 -75,713 -75,887 -76,264 -75,863

Annual Metrics And Ratios for Johnson & Johnson

This table displays calculated financial ratios and metrics derived from Johnson & Johnson's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/3/2016 1/1/2017 12/31/2017 12/30/2018 12/29/2019 1/3/2021 1/2/2022 1/1/2023 12/31/2023 12/29/2024 12/28/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-5.73% 2.59% 6.34% 6.71% 0.59% 0.64% -4.65% 1.59% 6.46% 4.30% 6.05%
EBITDA Growth
-6.25% 2.35% -0.21% 6.11% -4.04% -1.98% 12.09% -2.18% -15.53% 6.30% 70.58%
EBIT Growth
-6.70% 2.76% -9.62% 0.94% -6.00% -4.06% 16.40% -0.84% -23.88% 10.55% 101.71%
NOPAT Growth
-15.30% 20.73% -92.14% 1,158.21% 2.75% 0.53% 5.93% -8.34% 11.19% -6.54% 18.63%
Net Income Growth
-5.60% 7.34% -92.14% 1,076.69% -1.16% -2.68% 41.89% -14.07% 95.94% -59.99% 90.56%
EPS Growth
-3.86% 8.21% -92.07% 1,093.62% 0.36% -2.13% 41.74% -13.83% 103.86% -57.80% 90.50%
Operating Cash Flow Growth
4.59% -4.10% 12.20% 5.44% 5.47% 0.51% -0.54% -9.47% 7.54% 6.47% 1.09%
Free Cash Flow Firm Growth
-30.36% -16.99% -238.95% 221.60% -19.34% -38.17% 32.15% 25.75% -13.34% -46.40% -154.53%
Invested Capital Growth
-5.03% 5.70% 37.40% -8.96% -2.60% 8.22% 3.83% -3.61% 2.40% 11.20% 30.83%
Revenue Q/Q Growth
-0.63% 0.41% 2.81% 0.24% 0.43% 2.14% -13.89% 3.60% 11.59% 1.28% 2.22%
EBITDA Q/Q Growth
4.86% 2.42% -3.42% 1.17% 4.86% -9.07% -1.96% 4.20% 11.51% -3.37% 3.40%
EBIT Q/Q Growth
5.60% 2.77% -8.34% 2.38% 6.44% -13.10% -2.21% 6.23% 17.84% -5.13% 3.83%
NOPAT Q/Q Growth
-7.01% 8.77% -91.64% 937.45% 0.51% -0.71% -10.68% 3.89% 6.57% -2.26% 11.29%
Net Income Q/Q Growth
4.72% 3.76% -91.79% 892.02% 6.84% -13.38% 16.77% -6.35% 1.53% -4.21% 6.71%
EPS Q/Q Growth
4.78% 4.22% -91.84% 867.24% 7.24% -13.36% 16.74% -6.27% 1.93% -2.85% 6.47%
Operating Cash Flow Q/Q Growth
2.52% 9.12% -2.54% 0.63% 0.66% 9.01% -10.03% -1.77% 12.39% -3.50% 1.35%
Free Cash Flow Firm Q/Q Growth
-15.64% 35.84% -10.64% 31.38% -21.82% -23.50% -16.87% 16.14% 35.87% -8.57% -125.38%
Invested Capital Q/Q Growth
-2.52% -6.22% -17.73% -9.04% -2.17% 2.80% 4.05% 1.20% -3.17% -2.35% 2.69%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
69.27% 69.69% 66.72% 66.79% 66.42% 65.58% 70.28% 69.25% 68.82% 69.07% 67.88%
EBITDA Margin
33.34% 33.27% 31.22% 31.04% 29.61% 28.84% 33.91% 32.65% 25.90% 26.40% 42.46%
Operating Margin
25.05% 28.34% 23.78% 24.27% 24.15% 23.60% 25.19% 24.95% 24.90% 23.42% 26.85%
EBIT Margin
28.00% 28.04% 23.84% 22.55% 21.07% 20.09% 24.52% 23.93% 17.11% 18.14% 34.50%
Profit (Net Income) Margin
21.99% 23.01% 1.70% 18.75% 18.42% 17.82% 26.52% 22.43% 41.28% 15.84% 28.46%
Tax Burden Percent
80.27% 83.52% 7.36% 84.99% 87.25% 89.19% 108.86% 92.68% 233.39% 84.29% 82.27%
Interest Burden Percent
97.84% 98.22% 96.99% 97.86% 100.23% 99.46% 99.33% 101.12% 103.36% 103.58% 100.26%
Effective Tax Rate
19.73% 16.48% 92.64% 15.01% 12.75% 10.81% 7.18% 15.44% 11.53% 15.71% 17.73%
Return on Invested Capital (ROIC)
26.08% 31.43% 2.02% 23.04% 25.17% 24.63% 24.62% 22.56% 25.25% 22.09% 21.56%
ROIC Less NNEP Spread (ROIC-NNEP)
18.07% 34.28% -2.93% 11.34% 1.28% -4.36% 65.01% -149.26% 1,110.70% -15.39% 51.61%
Return on Net Nonoperating Assets (RNNOA)
-4.21% -8.06% -0.03% 2.47% 0.19% -0.65% 5.79% 1.23% 23.04% -2.03% 13.47%
Return on Equity (ROE)
21.87% 23.37% 1.99% 25.51% 25.36% 23.97% 30.41% 23.79% 48.29% 20.06% 35.03%
Cash Return on Invested Capital (CROIC)
31.24% 25.88% -29.48% 32.42% 27.80% 16.73% 20.87% 26.23% 22.88% 11.48% -5.15%
Operating Return on Assets (OROA)
14.88% 14.68% 12.21% 11.86% 11.13% 9.97% 10.82% 10.37% 8.21% 9.27% 17.13%
Return on Assets (ROA)
11.68% 12.05% 0.87% 9.86% 9.73% 8.85% 11.70% 9.71% 19.81% 8.09% 14.13%
Return on Common Equity (ROCE)
21.87% 23.37% 1.99% 25.51% 25.36% 23.97% 30.41% 23.79% 48.29% 20.06% 35.03%
Return on Equity Simple (ROE_SIMPLE)
21.66% 23.49% 2.16% 25.60% 25.42% 23.25% 28.20% 23.36% 51.11% 19.68% 0.00%
Net Operating Profit after Tax (NOPAT)
14,093 17,014 1,337 16,826 17,288 17,380 18,410 16,874 18,763 17,536 20,803
NOPAT Margin
20.11% 23.67% 1.75% 20.62% 21.07% 21.05% 23.38% 21.10% 22.03% 19.74% 22.09%
Net Nonoperating Expense Percent (NNEP)
8.02% -2.85% 4.96% 11.70% 23.89% 28.98% -40.38% 171.82% -1,085.45% 37.48% -30.05%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 14.49% 19.13% 16.22% 16.07%
Cost of Revenue to Revenue
30.73% 30.31% 33.28% 33.21% 33.58% 34.42% 29.72% 30.75% 31.18% 30.93% 32.12%
SG&A Expenses to Revenue
30.26% 27.91% 28.15% 27.63% 27.03% 26.74% 25.55% 25.31% 25.26% 25.75% 25.14%
R&D to Revenue
13.23% 12.76% 14.39% 14.59% 14.92% 14.94% 19.27% 18.65% 18.08% 19.64% 15.66%
Operating Expenses to Revenue
44.21% 41.35% 42.94% 42.52% 42.27% 41.98% 45.09% 44.30% 43.92% 45.65% 41.03%
Earnings before Interest and Taxes (EBIT)
19,620 20,161 18,222 18,393 17,289 16,587 19,308 19,145 14,573 16,110 32,496
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
23,366 23,915 23,864 25,322 24,298 23,818 26,698 26,115 22,059 23,449 39,999
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.17 3.63 5.22 4.91 5.70 5.95 5.66 5.66 5.32 4.89 6.13
Price to Tangible Book Value (P/TBV)
9.49 12.33 0.00 0.00 0.00 0.00 0.00 191.57 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.22 3.56 4.11 3.60 4.13 4.56 5.33 5.43 4.29 3.93 5.31
Price to Earnings (P/E)
14.64 15.46 241.73 19.19 22.43 25.57 20.08 24.22 10.40 24.83 18.66
Dividend Yield
3.62% 3.35% 2.84% 3.23% 2.91% 2.78% 2.63% 2.68% 3.09% 3.39% 2.48%
Earnings Yield
6.83% 6.47% 0.41% 5.21% 4.46% 3.91% 4.98% 4.13% 9.61% 4.03% 5.36%
Enterprise Value to Invested Capital (EV/IC)
3.93 4.33 4.32 4.37 5.13 5.27 5.53 6.15 4.95 4.32 4.83
Enterprise Value to Revenue (EV/Rev)
2.95 3.35 4.32 3.73 4.24 4.68 5.35 5.65 4.37 4.07 5.61
Enterprise Value to EBITDA (EV/EBITDA)
8.86 10.08 13.85 12.02 14.30 16.22 15.79 17.30 16.87 15.41 13.20
Enterprise Value to EBIT (EV/EBIT)
10.55 11.95 18.14 16.54 20.10 23.29 21.83 23.60 25.54 22.43 16.25
Enterprise Value to NOPAT (EV/NOPAT)
14.69 14.16 247.16 18.09 20.10 22.23 22.89 26.78 19.83 20.61 25.38
Enterprise Value to Operating Cash Flow (EV/OCF)
10.58 12.84 15.70 13.71 14.84 16.41 18.00 21.32 16.33 14.89 21.53
Enterprise Value to Free Cash Flow (EV/FCFF)
12.26 17.20 0.00 12.85 18.20 32.72 27.01 23.03 21.89 39.65 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.28 0.39 0.57 0.51 0.47 0.56 0.46 0.52 0.43 0.51 0.59
Long-Term Debt to Equity
0.18 0.32 0.51 0.46 0.45 0.52 0.41 0.35 0.38 0.43 0.48
Financial Leverage
-0.23 -0.24 0.01 0.22 0.15 0.15 0.09 -0.01 0.02 0.13 0.26
Leverage Ratio
1.87 1.94 2.29 2.59 2.61 2.71 2.60 2.45 2.44 2.48 2.48
Compound Leverage Factor
1.83 1.91 2.22 2.53 2.61 2.70 2.58 2.48 2.52 2.57 2.49
Debt to Total Capital
21.82% 27.81% 36.50% 33.78% 31.77% 35.79% 31.32% 34.04% 29.90% 33.88% 37.02%
Short-Term Debt to Total Capital
7.70% 4.80% 4.12% 3.10% 1.38% 2.67% 3.49% 10.95% 3.52% 5.53% 6.56%
Long-Term Debt to Total Capital
14.13% 23.01% 32.38% 30.68% 30.39% 33.12% 27.82% 23.09% 26.38% 28.35% 30.46%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
78.18% 72.19% 63.50% 66.22% 68.23% 64.21% 68.68% 65.96% 70.10% 66.12% 62.98%
Debt to EBITDA
0.85 1.13 1.45 1.20 1.14 1.48 1.26 1.52 1.33 1.56 1.20
Net Debt to EBITDA
-0.79 -0.62 0.68 0.43 0.35 0.42 0.08 0.66 0.29 0.52 0.70
Long-Term Debt to EBITDA
0.55 0.94 1.29 1.09 1.09 1.37 1.12 1.03 1.17 1.31 0.99
Debt to NOPAT
1.41 1.59 25.86 1.81 1.60 2.03 1.83 2.35 1.56 2.09 2.30
Net Debt to NOPAT
-1.31 -0.87 12.18 0.64 0.49 0.58 0.12 1.03 0.34 0.69 1.34
Long-Term Debt to NOPAT
0.91 1.32 22.94 1.65 1.53 1.88 1.63 1.59 1.38 1.75 1.90
Altman Z-Score
4.57 4.57 3.81 3.91 4.01 3.78 4.16 4.08 4.35 3.97 4.76
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.17 2.47 1.41 1.47 1.26 1.21 1.35 0.99 1.16 1.11 1.03
Quick Ratio
1.77 2.04 1.04 1.08 0.94 0.91 1.04 0.65 0.82 0.78 0.69
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
16,881 14,012 -19,471 23,676 19,097 11,807 15,603 19,621 17,003 9,113 -4,970
Operating Cash Flow to CapEx
0.00% 957.99% 1,455.15% 4,753.96% 10,049.79% 773.70% 795.99% 611.48% 544.59% 647.27% 596.55%
Free Cash Flow to Firm to Interest Expense
30.58 19.30 -20.85 23.56 60.05 58.74 85.26 71.09 22.02 12.07 -5.12
Operating Cash Flow to Interest Expense
35.45 25.85 22.54 22.09 73.64 117.09 127.92 76.79 29.52 32.14 25.26
Operating Cash Flow Less CapEx to Interest Expense
35.45 23.15 20.99 21.63 72.90 101.96 111.85 64.23 24.10 27.17 21.03
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.53 0.52 0.51 0.53 0.53 0.50 0.44 0.43 0.48 0.51 0.50
Accounts Receivable Turnover
6.45 6.41 6.07 5.91 5.74 5.89 5.46 5.46 5.89 5.98 5.88
Inventory Turnover
2.65 2.69 3.01 3.12 3.13 3.10 2.37 2.38 2.48 2.33 2.27
Fixed Asset Turnover
4.38 4.52 4.65 4.79 4.73 4.53 4.17 4.33 4.50 4.40 4.31
Accounts Payable Turnover
3.01 3.21 3.58 3.65 3.43 3.15 2.28 2.35 2.72 2.76 2.71
Days Sales Outstanding (DSO)
56.56 56.95 60.13 61.72 63.56 62.00 66.89 66.90 61.96 61.06 62.04
Days Inventory Outstanding (DIO)
137.60 135.66 121.31 116.97 116.69 117.90 153.87 153.26 147.42 156.95 160.66
Days Payable Outstanding (DPO)
121.19 113.79 102.07 100.02 106.50 115.87 160.34 155.40 134.17 132.49 134.52
Cash Conversion Cycle (CCC)
72.97 78.82 79.36 78.67 73.75 64.02 60.42 64.75 75.21 85.52 88.18
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
52,635 55,637 76,445 69,595 67,786 73,359 76,166 73,419 75,179 83,602 109,375
Invested Capital Turnover
1.30 1.33 1.16 1.12 1.19 1.17 1.05 1.07 1.15 1.12 0.98
Increase / (Decrease) in Invested Capital
-2,788 3,002 20,808 -6,850 -1,809 5,573 2,807 -2,747 1,760 8,423 25,773
Enterprise Value (EV)
207,028 240,973 330,529 304,303 347,556 386,341 421,449 451,852 372,143 361,338 528,073
Market Capitalization
225,543 255,754 314,244 293,510 339,147 376,260 419,306 434,491 365,738 349,226 500,242
Book Value per Share
$25.71 $25.88 $22.39 $22.28 $22.60 $24.04 $28.12 $29.38 $28.57 $29.69 $33.85
Tangible Book Value per Share
$8.59 $7.62 ($9.30) ($6.83) ($8.29) ($10.07) ($2.89) $0.87 ($0.81) ($4.29) ($7.32)
Total Capital
91,011 97,544 94,741 90,232 87,167 98,544 107,774 116,446 98,106 108,124 129,477
Total Debt
19,861 27,126 34,581 30,480 27,696 35,266 33,751 39,642 29,332 36,634 47,933
Total Long-Term Debt
12,857 22,442 30,675 27,684 26,494 32,635 29,985 26,886 25,881 30,651 39,438
Net Debt
-18,515 -14,781 16,285 10,793 8,409 10,081 2,143 17,361 6,405 12,112 27,831
Capital Expenditures (CapEx)
-1.00 1,959 1,447 467 233 3,042 2,941 3,466 4,185 3,749 4,112
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,091 1,522 -1,839 -2,088 -8,775 -13,810 -12,089 -10,033 -12,263 -12,967 -10,109
Debt-free Net Working Capital (DFNWC)
39,467 43,429 16,457 17,599 10,512 11,375 19,519 12,248 10,664 11,555 9,993
Net Working Capital (NWC)
32,463 38,745 12,551 14,803 9,310 8,744 15,753 -508 7,213 5,572 1,498
Net Nonoperating Expense (NNE)
-1,316 474 37 1,529 2,169 2,666 -2,468 -1,067 -16,390 3,470 -6,001
Net Nonoperating Obligations (NNO)
-18,515 -14,781 16,285 9,843 8,315 10,081 2,143 -3,385 6,405 12,112 27,831
Total Depreciation and Amortization (D&A)
3,746 3,754 5,642 6,929 7,009 7,231 7,390 6,970 7,486 7,339 7,503
Debt-free, Cash-free Net Working Capital to Revenue
1.56% 2.12% -2.41% -2.56% -10.69% -16.72% -15.35% -12.54% -14.40% -14.60% -10.73%
Debt-free Net Working Capital to Revenue
56.32% 60.41% 21.53% 21.57% 12.81% 13.77% 24.79% 15.31% 12.52% 13.01% 10.61%
Net Working Capital to Revenue
46.33% 53.89% 16.42% 18.15% 11.35% 10.59% 20.01% -0.64% 8.47% 6.27% 1.59%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$5.56 $6.04 $0.48 $0.00 $5.72 $5.59 $7.93 $6.83 $13.88 $5.84 $11.13
Adjusted Weighted Average Basic Shares Outstanding
2.77B 2.74B 2.69B 0.00 2.65B 2.63B 2.63B 2.63B 2.53B 2.41B 2.41B
Adjusted Diluted Earnings per Share
$5.48 $5.93 $0.47 $0.00 $5.63 $5.51 $7.81 $6.73 $13.72 $5.79 $11.03
Adjusted Weighted Average Diluted Shares Outstanding
2.81B 2.79B 2.75B 0.00 2.68B 2.67B 2.67B 2.66B 2.56B 2.43B 2.43B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.76B 2.71B 2.68B 0.00 2.63B 2.63B 2.63B 2.60B 2.41B 2.41B 2.41B
Normalized Net Operating Profit after Tax (NOPAT)
14,501 17,425 12,942 17,039 17,520 17,600 18,604 17,107 19,195 17,734 20,991
Normalized NOPAT Margin
20.69% 24.24% 16.93% 20.89% 21.35% 21.31% 23.63% 21.39% 22.54% 19.97% 22.29%
Pre Tax Income Margin
27.39% 27.55% 23.12% 22.06% 21.12% 19.98% 24.36% 24.20% 17.69% 18.79% 34.59%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
35.54 27.77 19.51 18.30 54.37 82.52 105.51 69.37 18.88 21.34 33.47
NOPAT to Interest Expense
25.53 23.44 1.43 16.74 54.37 86.47 100.60 61.14 24.30 23.23 21.42
EBIT Less CapEx to Interest Expense
35.55 25.07 17.96 17.84 53.64 67.39 89.44 56.81 13.46 16.37 29.23
NOPAT Less CapEx to Interest Expense
25.53 20.74 -0.12 16.28 53.63 71.33 84.53 48.58 18.88 18.26 17.19
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
53.04% 52.12% 687.92% 62.06% 65.59% 71.23% 52.84% 65.11% 33.48% 84.05% 46.19%
Augmented Payout Ratio
87.37% 106.41% 1,177.00% 100.42% 110.21% 93.12% 69.39% 98.75% 47.86% 101.34% 68.40%

Quarterly Metrics And Ratios for Johnson & Johnson

This table displays calculated financial ratios and metrics derived from Johnson & Johnson's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/29/2024 3/30/2025 6/29/2025 9/28/2025 12/28/2025 3/29/2026 6/28/2026
DEI Shares Outstanding
- - - - - - - - - 2,409,898,936.00 2,407,216,971.00
DEI Adjusted Shares Outstanding
- - - - - - - - - 2,409,898,936.00 2,407,216,971.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - 2.17 2.30
Growth Metrics
- - - - - - - - - - -
Revenue Growth
70.51% 2.34% 4.31% 5.25% 5.26% 2.39% 5.77% 6.77% 9.08% 9.91% 6.60%
EBITDA Growth
54.47% 776.44% -8.93% -25.92% -12.67% 187.12% 14.54% 82.65% 23.32% -47.38% 3.37%
EBIT Growth
91.61% 375.33% -9.26% -35.67% -18.88% 285.25% 16.29% 131.89% 32.06% -55.32% 4.13%
NOPAT Growth
50.81% 30.55% 3.24% -11.06% -11.93% -3.68% 10.80% 18.95% 76.80% 10.85% 3.30%
Net Income Growth
15.03% 4,886.76% -8.90% -89.65% -15.26% 237.91% 18.16% 91.24% 49.11% -52.40% -0.05%
EPS Growth
19.70% 4,566.67% -1.53% -89.13% -10.76% 238.81% 18.65% 90.99% 47.52% -52.86% -0.87%
Operating Cash Flow Growth
46.97% 12.28% 34.70% 6.73% -11.19% 14.14% -31.16% 14.71% 4.67% -39.77% 122.18%
Free Cash Flow Firm Growth
-64.31% 291.51% 190.99% -651.44% -387.49% -147.66% -254.77% -310.93% -283.62% -85.77% 117.29%
Invested Capital Growth
2.40% -15.34% -6.37% 10.27% 11.20% 18.27% 26.04% 24.41% 30.83% 24.61% 2.62%
Revenue Q/Q Growth
0.21% -0.06% 4.98% 0.11% 0.22% -2.78% 8.45% 1.05% 2.38% -2.04% 5.19%
EBITDA Q/Q Growth
-5.93% -17.61% 39.19% -31.33% 10.89% 170.88% -44.47% 9.50% -25.13% 15.57% 9.10%
EBIT Q/Q Growth
-8.36% -24.04% 60.43% -42.40% 15.56% 260.75% -51.57% 14.86% -34.19% 22.05% 12.86%
NOPAT Q/Q Growth
-21.46% 44.25% -1.20% -20.55% -22.22% 57.77% 13.65% -14.70% 15.60% -1.08% 5.91%
Net Income Q/Q Growth
-84.44% -19.61% 43.96% -42.51% 27.36% 220.58% -49.66% -6.95% -0.70% 2.33% 5.71%
EPS Q/Q Growth
-84.53% -15.19% 44.03% -42.49% 27.03% 221.99% -49.56% -7.42% -1.89% 2.88% 6.07%
Operating Cash Flow Q/Q Growth
4.99% -53.49% 54.03% 41.90% -12.64% -40.23% -7.09% 136.44% -20.29% -65.60% 242.72%
Free Cash Flow Firm Q/Q Growth
451.81% 949.86% -42.39% -135.31% -34.60% -74.06% -87.06% 6.24% -25.66% 15.71% 117.41%
Invested Capital Q/Q Growth
-3.17% 3.00% 13.07% -2.22% -2.35% 9.54% 20.50% -3.48% 2.69% 4.34% -0.77%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
68.23% 69.55% 69.40% 69.01% 68.35% 66.40% 67.87% 69.56% 67.56% 66.31% 68.19%
EBITDA Margin
30.18% 24.88% 32.99% 22.63% 25.04% 69.77% 35.72% 38.71% 28.31% 33.40% 34.64%
Operating Margin
19.60% 27.63% 27.96% 22.42% 15.91% 28.24% 27.99% 29.31% 22.09% 26.29% 28.21%
EBIT Margin
21.57% 16.39% 25.05% 14.41% 16.62% 61.68% 27.54% 31.31% 20.12% 25.07% 26.90%
Profit (Net Income) Margin
18.93% 15.22% 20.88% 11.99% 15.24% 50.24% 23.32% 21.47% 20.83% 21.76% 21.86%
Tax Burden Percent
83.90% 87.64% 81.52% 80.71% 88.27% 80.69% 85.30% 68.76% 103.02% 87.40% 82.02%
Interest Burden Percent
104.59% 105.96% 102.22% 103.06% 103.85% 100.95% 99.27% 99.76% 100.47% 99.29% 99.09%
Effective Tax Rate
14.38% 12.36% 18.48% 19.29% 11.73% 19.31% 14.70% 31.24% -3.02% 12.60% 17.98%
Return on Invested Capital (ROIC)
19.23% 24.56% 21.80% 19.44% 15.71% 24.09% 21.87% 19.33% 22.22% 21.53% 20.27%
ROIC Less NNEP Spread (ROIC-NNEP)
49.63% 10.83% 19.20% 6.89% 18.62% 81.65% 21.32% 20.82% 19.84% 20.26% 19.20%
Return on Net Nonoperating Assets (RNNOA)
1.03% 2.15% 4.30% 1.07% 2.46% 11.51% 6.81% 5.95% 5.18% 5.90% 7.07%
Return on Equity (ROE)
20.26% 26.72% 26.09% 20.50% 18.17% 35.60% 28.67% 25.28% 27.39% 27.43% 27.33%
Cash Return on Invested Capital (CROIC)
22.88% 38.23% 26.90% 12.21% 11.48% 3.71% -5.08% -2.30% -5.15% -1.06% 16.77%
Operating Return on Assets (OROA)
10.35% 7.63% 11.64% 7.34% 8.49% 30.14% 13.33% 15.55% 9.99% 12.25% 13.36%
Return on Assets (ROA)
9.08% 7.09% 9.70% 6.11% 7.78% 24.55% 11.29% 10.66% 10.34% 10.63% 10.86%
Return on Common Equity (ROCE)
20.26% 26.72% 25.87% 20.50% 18.17% 35.60% 28.67% 25.28% 27.39% 27.43% 27.33%
Return on Equity Simple (ROE_SIMPLE)
0.00% 54.95% 53.14% 20.93% 0.00% 27.92% 28.88% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
3,590 5,179 5,116 4,065 3,162 4,988 5,669 4,836 5,590 5,530 5,856
NOPAT Margin
16.78% 24.22% 22.79% 18.09% 14.04% 22.79% 23.88% 20.15% 22.76% 22.98% 23.14%
Net Nonoperating Expense Percent (NNEP)
-30.40% 13.73% 2.60% 12.54% -2.91% -57.56% 0.55% -1.48% 2.37% 1.27% 1.07%
Return On Investment Capital (ROIC_SIMPLE)
3.66% - - - 2.92% 3.83% 4.39% 3.87% 4.32% 4.06% 4.37%
Cost of Revenue to Revenue
31.77% 30.45% 30.60% 30.99% 31.65% 33.60% 32.13% 30.44% 32.44% 33.69% 31.81%
SG&A Expenses to Revenue
27.16% 24.59% 25.31% 24.38% 28.65% 23.35% 24.80% 24.68% 27.49% 25.08% 25.41%
R&D to Revenue
21.21% 16.56% 16.19% 22.04% 23.60% 14.73% 14.81% 15.30% 17.64% 14.81% 14.43%
Operating Expenses to Revenue
48.63% 41.92% 41.44% 46.60% 52.44% 38.16% 39.88% 40.25% 45.47% 40.02% 39.98%
Earnings before Interest and Taxes (EBIT)
4,614 3,505 5,623 3,239 3,743 13,503 6,539 7,511 4,943 6,033 6,809
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
6,457 5,320 7,405 5,085 5,639 15,275 8,482 9,288 6,954 8,037 8,768
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
5.32 5.39 4.92 5.54 4.89 5.05 4.67 5.46 6.13 7.14 7.21
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
4.29 4.41 4.06 4.43 3.93 4.41 4.05 4.70 5.31 6.01 6.26
Price to Earnings (P/E)
10.40 9.82 9.25 26.46 24.83 18.07 16.18 17.23 18.66 27.54 29.14
Dividend Yield
3.09% 3.03% 3.29% 3.01% 3.39% 3.03% 3.29% 2.83% 2.48% 2.16% 2.06%
Earnings Yield
9.61% 10.19% 10.81% 3.78% 4.03% 5.53% 6.18% 5.80% 5.36% 3.63% 3.43%
Enterprise Value to Invested Capital (EV/IC)
4.95 4.97 4.20 4.72 4.32 4.45 3.61 4.32 4.83 5.37 5.66
Enterprise Value to Revenue (EV/Rev)
4.37 4.50 4.25 4.61 4.07 4.56 4.40 4.99 5.61 6.36 6.55
Enterprise Value to EBITDA (EV/EBITDA)
16.87 14.39 14.12 16.65 15.41 12.20 11.56 11.89 13.20 18.69 19.41
Enterprise Value to EBIT (EV/EBIT)
25.54 19.90 19.59 23.79 22.43 15.61 14.75 14.70 16.25 24.47 25.35
Enterprise Value to NOPAT (EV/NOPAT)
19.83 21.10 19.98 22.52 20.61 23.59 22.43 24.61 25.38 28.54 29.63
Enterprise Value to Operating Cash Flow (EV/OCF)
16.33 16.61 14.92 16.07 14.89 16.45 17.31 19.01 21.53 26.78 23.23
Enterprise Value to Free Cash Flow (EV/FCFF)
21.89 11.93 15.10 40.53 39.65 130.11 0.00 0.00 0.00 0.00 34.20
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.43 0.48 0.58 0.51 0.51 0.67 0.65 0.58 0.59 0.68 0.58
Long-Term Debt to Equity
0.38 0.36 0.44 0.45 0.43 0.49 0.50 0.50 0.48 0.46 0.44
Financial Leverage
0.02 0.20 0.22 0.15 0.13 0.14 0.32 0.29 0.26 0.29 0.37
Leverage Ratio
2.44 2.61 2.52 2.44 2.48 2.47 2.50 2.48 2.48 2.48 2.41
Compound Leverage Factor
2.55 2.77 2.58 2.51 2.57 2.49 2.48 2.48 2.49 2.46 2.39
Debt to Total Capital
29.90% 32.45% 36.71% 33.76% 33.88% 40.08% 39.28% 36.61% 37.02% 40.38% 36.59%
Short-Term Debt to Total Capital
3.52% 8.25% 8.72% 4.21% 5.53% 10.66% 8.92% 5.11% 6.56% 12.82% 8.72%
Long-Term Debt to Total Capital
26.38% 24.20% 27.99% 29.54% 28.35% 29.42% 30.36% 31.51% 30.46% 27.56% 27.87%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
70.10% 67.55% 63.29% 66.24% 66.12% 59.92% 60.72% 63.39% 62.98% 59.62% 63.41%
Debt to EBITDA
1.33 1.26 1.59 1.47 1.56 1.56 1.47 1.18 1.20 1.68 1.48
Net Debt to EBITDA
0.29 0.28 0.61 0.64 0.52 0.40 0.92 0.70 0.70 1.01 0.86
Long-Term Debt to EBITDA
1.17 0.94 1.21 1.29 1.31 1.15 1.14 1.02 0.99 1.15 1.13
Debt to NOPAT
1.56 1.84 2.25 1.99 2.09 3.02 2.86 2.45 2.30 2.56 2.27
Net Debt to NOPAT
0.34 0.41 0.87 0.86 0.69 0.78 1.79 1.46 1.34 1.54 1.31
Long-Term Debt to NOPAT
1.38 1.37 1.72 1.74 1.75 2.22 2.21 2.11 1.90 1.75 1.73
Altman Z-Score
4.16 4.10 3.73 3.94 3.74 4.00 3.69 4.13 4.30 4.67 4.99
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.16 1.17 1.07 1.03 1.11 1.26 1.01 1.07 1.03 1.03 1.09
Quick Ratio
0.82 0.84 0.77 0.70 0.78 0.96 0.68 0.71 0.69 0.69 0.73
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
1,830 19,213 11,068 -3,909 -5,261 -9,158 -17,131 -16,062 -20,183 -17,012 2,961
Operating Cash Flow to CapEx
535.63% 612.56% 918.92% 816.45% 447.63% 808.91% 391.72% 625.44% 641.14% 246.47% 684.90%
Free Cash Flow to Firm to Interest Expense
12.12 123.95 40.99 -20.25 -38.40 -44.89 -55.62 -65.56 -94.31 -62.55 10.54
Operating Cash Flow to Interest Expense
52.07 23.59 20.86 41.41 50.97 20.46 12.59 37.42 34.15 9.24 30.66
Operating Cash Flow Less CapEx to Interest Expense
42.35 19.74 18.59 36.34 39.58 17.93 9.38 31.44 28.83 5.49 26.19
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.48 0.47 0.46 0.51 0.51 0.49 0.48 0.50 0.50 0.49 0.50
Accounts Receivable Turnover
5.89 5.47 5.32 5.66 5.98 5.77 5.39 5.46 5.88 5.71 5.31
Inventory Turnover
2.48 2.18 2.14 2.28 2.33 2.36 2.27 2.20 2.27 2.28 2.20
Fixed Asset Turnover
4.50 4.30 4.29 4.46 4.40 4.41 4.35 4.30 4.31 4.37 4.30
Accounts Payable Turnover
2.72 2.92 2.78 3.14 2.76 3.20 3.18 3.17 2.71 3.10 3.36
Days Sales Outstanding (DSO)
61.96 66.69 68.66 64.45 61.06 63.26 67.74 66.91 62.04 63.90 68.75
Days Inventory Outstanding (DIO)
147.42 167.38 170.73 160.04 156.95 154.95 160.56 165.95 160.66 160.35 165.82
Days Payable Outstanding (DPO)
134.17 125.11 131.44 116.39 132.49 114.20 114.94 115.27 134.52 117.75 108.51
Cash Conversion Cycle (CCC)
75.21 108.95 107.95 108.11 85.52 104.01 113.37 117.60 88.18 106.50 126.06
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
75,179 77,434 87,554 85,612 83,602 91,580 110,354 106,510 109,375 114,122 113,249
Invested Capital Turnover
1.15 1.01 0.96 1.07 1.12 1.06 0.92 0.96 0.98 0.94 0.88
Increase / (Decrease) in Invested Capital
1,760 -14,034 -5,952 7,974 8,423 14,146 22,800 20,898 25,773 22,542 2,895
Enterprise Value (EV)
372,143 385,168 367,776 403,983 361,338 407,622 398,591 460,036 528,073 612,396 641,300
Market Capitalization
365,738 377,754 351,760 388,529 349,226 394,151 366,710 432,803 500,242 579,460 613,022
Book Value per Share
$28.57 $29.08 $29.72 $29.14 $29.69 $32.44 $32.61 $32.92 $33.85 $33.69 $35.30
Tangible Book Value per Share
($0.81) ($0.37) ($5.17) ($5.87) ($4.29) ($1.29) ($8.10) ($7.27) ($7.32) ($6.82) ($4.88)
Total Capital
98,106 103,652 113,029 105,909 108,124 130,361 129,234 125,072 129,477 136,173 134,007
Total Debt
29,332 33,632 41,491 35,751 36,634 52,252 50,761 45,795 47,933 54,987 49,036
Total Long-Term Debt
25,881 25,082 31,636 31,289 30,651 38,355 39,235 39,408 39,438 37,527 37,344
Net Debt
6,405 7,414 16,016 15,454 12,112 13,471 31,881 27,233 27,831 32,936 28,278
Capital Expenditures (CapEx)
1,468 597 613 979 1,560 516 990 1,466 1,140 1,020 1,258
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-12,263 -9,391 -11,736 -14,345 -12,967 -10,236 -7,036 -8,433 -10,109 -3,134 -4,187
Debt-free Net Working Capital (DFNWC)
10,664 16,827 13,739 5,952 11,555 28,545 11,844 10,129 9,993 18,917 16,571
Net Working Capital (NWC)
7,213 8,277 3,884 1,490 5,572 14,648 318 3,742 1,498 1,457 4,879
Net Nonoperating Expense (NNE)
-459 1,924 430 1,371 -269 -6,011 132 -316 474 295 322
Net Nonoperating Obligations (NNO)
6,405 7,414 16,016 15,454 12,112 13,471 31,881 27,233 27,831 32,936 28,278
Total Depreciation and Amortization (D&A)
1,843 1,815 1,782 1,846 1,896 1,772 1,943 1,777 2,011 2,004 1,959
Debt-free, Cash-free Net Working Capital to Revenue
-14.40% -10.96% -13.56% -16.36% -14.60% -11.46% -7.76% -9.15% -10.73% -3.25% -4.28%
Debt-free Net Working Capital to Revenue
12.52% 19.65% 15.87% 6.79% 13.01% 31.95% 13.07% 10.99% 10.61% 19.63% 16.92%
Net Working Capital to Revenue
8.47% 9.66% 4.49% 1.70% 6.27% 16.40% 0.35% 4.06% 1.59% 1.51% 4.98%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.61 $1.35 $1.95 $1.12 $1.42 $4.57 $2.30 $2.14 $2.12 $2.17 $2.30
Adjusted Weighted Average Basic Shares Outstanding
2.53B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B
Adjusted Diluted Earnings per Share
$1.58 $1.34 $1.93 $1.11 $1.41 $4.54 $2.29 $2.12 $2.08 $2.14 $2.27
Adjusted Weighted Average Diluted Shares Outstanding
2.56B 2.43B 2.42B 2.43B 2.43B 2.42B 2.42B 2.43B 2.43B 2.45B 2.44B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B 2.41B
Normalized Net Operating Profit after Tax (NOPAT)
3,638 5,322 5,106 4,098 3,199 5,002 5,724 4,879 3,857 5,557 5,884
Normalized NOPAT Margin
17.00% 24.89% 22.75% 18.24% 14.20% 22.85% 24.11% 20.34% 15.70% 23.10% 23.25%
Pre Tax Income Margin
22.56% 17.37% 25.61% 14.85% 17.26% 62.26% 27.34% 31.23% 20.22% 24.89% 26.66%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
30.56 22.61 20.83 16.78 27.32 66.19 21.23 30.66 23.10 22.18 24.23
NOPAT to Interest Expense
23.78 33.41 18.95 21.06 23.08 24.45 18.41 19.74 26.12 20.33 20.84
EBIT Less CapEx to Interest Expense
20.83 18.76 18.56 11.71 15.93 63.66 18.02 24.67 17.77 18.43 19.75
NOPAT Less CapEx to Interest Expense
14.05 29.56 16.68 15.99 11.69 21.92 15.19 13.75 20.79 16.58 16.36
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
33.48% 30.40% 30.49% 79.71% 84.05% 54.76% 53.34% 48.70% 46.19% 59.52% 59.99%
Augmented Payout Ratio
47.86% 38.18% 37.71% 95.82% 101.34% 68.90% 66.35% 65.87% 68.40% 96.85% 98.38%

Financials Breakdown Chart

Key Financial Trends

Johnson & Johnson’s latest quarter shows a still-healthy, highly profitable business, but with some clear balance sheet and cash flow pressure from acquisitions, debt, and working-capital swings. In Q1 2026, revenue rose to about $24.1 billion and diluted EPS came in at $2.14. The company also generated $2.5 billion of operating cash flow, which remains a key strength for a dividend-paying healthcare giant.

  • Revenue growth remains steady. Q1 2026 revenue of $24.1 billion was up modestly from $23.9 billion in Q3 2025 and $21.9 billion in Q1 2025, showing resilient demand.
  • Profitability is solid. Q1 2026 net income attributable to common shareholders was $5.2 billion, with diluted EPS of $2.14.
  • Operating cash flow is still meaningful. JNJ produced $2.5 billion of operating cash flow in Q1 2026, supporting dividends and ongoing investment.
  • Gross profit margin remains strong. Q1 2026 gross profit was about $16.0 billion on $24.1 billion of revenue, indicating strong pricing power and product economics.
  • Long-term earnings power has improved versus 2024’s weak spots. After a softer 2024, 2025 and early 2026 show more stable quarterly earnings and revenue trends.
  • Dividend coverage looks manageable, but not effortless. JNJ paid $3.1 billion in dividends in Q1 2026, which is larger than quarterly operating cash flow in that period, so cash generation needs to remain consistent.
  • Heavy R&D spending continues. Q1 2026 R&D expense was $3.6 billion, underscoring the company’s commitment to pipeline investment but also limiting near-term margin expansion.
  • The company still carries a very large amount of goodwill and intangibles. Goodwill was about $48.6 billion and intangible assets about $49.1 billion in Q1 2026, reflecting J&J’s acquisition-heavy history.
  • Liquidity is tighter than it was a year ago. Cash and equivalents fell to $21.7 billion in Q1 2026 from $38.5 billion in Q1 2025, while current liabilities remained elevated at $57.7 billion.
  • Debt remains substantial. Q1 2026 short-term debt was $17.5 billion and long-term debt was $37.5 billion, so leverage is still a factor investors should watch.
  • Acquisition and financing activity has been volatile. Cash flow from investing and financing was pressured by acquisitions, debt repayment, and share repurchases, which can weigh on flexibility.

Bottom line: Johnson & Johnson still looks like a fundamentally strong defensive healthcare name with reliable revenue, healthy margins, and strong dividend support. The main caution is that the balance sheet has become more levered and cash reserves are lower than they were a year ago, so investors should watch cash flow consistency and debt trends closely.

07/26/26 01:40 PM ETAI Generated. May Contain Errors.

Johnson & Johnson Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Johnson & Johnson's fiscal year ends in December. Their fiscal year 2025 ended on December 28, 2025.

Johnson & Johnson's net income appears to be on an upward trend, with a most recent value of $26.80 billion in 2025, rising from $15.41 billion in 2015. The previous period was $14.07 billion in 2024. See where experts think Johnson & Johnson is headed by visiting Johnson & Johnson's forecast page.

Johnson & Johnson's total operating income in 2025 was $25.29 billion, based on the following breakdown:
  • Total Gross Profit: $63.94 billion
  • Total Operating Expenses: $38.65 billion

Over the last 10 years, Johnson & Johnson's total revenue changed from $70.07 billion in 2015 to $94.19 billion in 2025, a change of 34.4%.

Johnson & Johnson's total liabilities were at $117.67 billion at the end of 2025, a 8.3% increase from 2024, and a 89.0% increase since 2015.

In the past 10 years, Johnson & Johnson's cash and equivalents has ranged from $12.89 billion in 2022 to $24.11 billion in 2024, and is currently $19.71 billion as of their latest financial filing in 2025.

Over the last 10 years, Johnson & Johnson's book value per share changed from 25.71 in 2015 to 33.85 in 2025, a change of 31.6%.



Financial statements for NYSE:JNJ last updated on 7/23/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners